Alprostadil (Caverject/MUSE) Cost in Indiana: 2026 Pricing, Insurance, and Savings Guide

What Alprostadil Costs at Indiana Pharmacies in 2026

The average cash price for brand-name Caverject or MUSE at Indiana retail pharmacies sits near $600 per month in 2026. This figure reflects the cost for a typical on-demand supply without any insurance or discount applied. Generic alprostadil injection is available, though retail savings over brand vary by pharmacy.

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that produces erection by directly relaxing penile smooth muscle and dilating cavernosal arteries. The FDA first approved Caverject (alprostadil for injection) in 1995, and MUSE (medicated urethral system for erection) followed shortly after. In the key trial by Linet and Ogrinc (NEJM, 1996, N=296), intracavernosal alprostadil produced erections sufficient for intercourse in 87% of injections at optimized doses, compared to 13% with placebo.

Pricing at individual Indiana pharmacies can fluctuate. A Walgreens or CVS in Indianapolis may price Caverject Impulse (20 mcg, 2-pack) differently than an independent pharmacy in Fort Wayne or Evansville. Patients should request cash-price quotes from at least two or three pharmacies before filling. GoodRx and RxSaver coupons occasionally bring the per-unit cost down by 15% to 30%, though availability of these discounts shifts month to month.

The cost per dose depends on the prescribed strength. A patient titrated to 10 mcg who uses the medication twice weekly will spend considerably less per month than someone requiring 40 mcg three times weekly. The Caverject prescribing information specifies that the lowest effective dose should be used, which also happens to be the most cost-effective approach.

Indiana Medicaid and Alprostadil Coverage

Indiana Medicaid does not cover alprostadil for standard erectile dysfunction. The state's fee-for-service formulary and managed care plans (such as those administered through Anthem, MDwise, and CareSource) exclude most ED medications from the pharmacy benefit.

This exclusion stems from federal Medicaid policy. Since 2006, the Deficit Reduction Act has allowed states to exclude erectile dysfunction drugs from Medicaid formularies, and Indiana exercises that option. The only scenario where alprostadil might receive Medicaid coverage in Indiana involves off-label indications unrelated to ED, such as its use in neonatal congenital heart disease (a distinct formulation, Prostin VR Pediatric), which falls under hospital billing rather than outpatient pharmacy.

For Indiana Medicaid enrollees who need ED treatment, the practical options are: paying cash at retail price, using a 503A compounding pharmacy, or pursuing manufacturer assistance programs. Some Medicaid managed care organizations may offer prior authorization pathways for ED drugs when erectile dysfunction is secondary to a covered condition (e.g., post-radical prostatectomy), but approvals are rare and require extensive documentation from the prescribing urologist.

Patients enrolled in Indiana's Healthy Indiana Plan (HIP) face the same exclusion. HIP 2.0 follows standard Medicaid pharmacy benefit restrictions, and alprostadil remains outside the covered formulary per CMS Medicaid drug coverage guidelines.

Private Insurance Coverage in Indiana

Several major commercial insurers operating in Indiana do include alprostadil on their formularies, though coverage varies sharply by plan tier and often requires prior authorization or step therapy.

Anthem Blue Cross Blue Shield, the largest commercial insurer in Indiana, covers Caverject on some employer-sponsored plans but typically places it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). That means a copay of $50 to $150 per fill after deductible, depending on the specific plan. MUSE may sit on a different tier than Caverject, and some Anthem plans cover one but not the other. Step therapy requirements often mandate that the patient try and fail a PDE5 inhibitor (sildenafil or tadalafil) before alprostadil is approved.

UnitedHealthcare plans in Indiana follow a similar pattern. Most UHC commercial formularies list alprostadil injection but require prior authorization documenting PDE5 inhibitor failure or contraindication. Patients with cardiovascular conditions that preclude PDE5 inhibitor use (unstable angina, recent stroke, concurrent nitrate therapy) can often get alprostadil authorized more quickly by submitting documentation from AUA guideline-concordant workup.

Self-funded employer plans, which cover approximately 60% of commercially insured Hoosiers according to Kaiser Family Foundation data, set their own formulary rules. Some self-funded plans exclude ED drugs entirely. Others cover them without restrictions. The only way to know is to call the pharmacy benefit manager listed on the back of the insurance card and request a formulary search for alprostadil.

Medicare Part D in Indiana generally does not cover erectile dysfunction medications. The Medicare Modernization Act of 2003 explicitly excluded ED drugs from Part D coverage, and that exclusion remains in effect through 2026. Medicare Advantage plans with supplemental drug benefits occasionally include ED coverage, but this is uncommon in Indiana-market MA plans.

Compounded Alprostadil in Indiana: Legality and Cost

Compounded alprostadil is legal in Indiana when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. This represents the most significant cost-reduction strategy available to Indiana patients.

Under FDA 503A provisions, a licensed compounding pharmacy may prepare alprostadil formulations for individual patients when a prescriber determines a clinical need, such as a specific dose not commercially available or a multi-drug combination (trimix or bimix). Indiana's Board of Pharmacy regulates these facilities under IC 25-26-13, and compounding pharmacies must hold a valid Indiana pharmacy license.

The most common compounded formulation prescribed in Indiana for ED is trimix, a combination of alprostadil, papaverine, and phentolamine. Trimix vials from Indiana-based 503A pharmacies or out-of-state 503A pharmacies that ship to Indiana typically cost $80 to $200 for a multi-dose vial supplying 10 to 20 injections. Per-dose cost can fall below $10. That is a dramatic reduction from the $30 to $75 per-dose cost of brand Caverject.

Dr. Irwin Goldstein, a urologist and editor of The Journal of Sexual Medicine, has noted that "compounded intracavernosal combinations have been the mainstay of injection therapy in clinical practice for decades, offering both dose flexibility and cost advantages over single-agent brand products." This reflects the reality that most urologists prescribing injection therapy in Indiana and nationally have long preferred compounded trimix over brand Caverject for cost and efficacy reasons.

Patients should verify that any compounding pharmacy they use is licensed and accredited, ideally through PCAB (Pharmacy Compounding Accreditation Board) accreditation. Contamination events at non-accredited compounding facilities have caused serious harm nationally, as documented in the 2012 NECC meningitis outbreak investigated by the CDC.

How Manufacturer Savings Programs Work in Indiana

Pfizer, the manufacturer of Caverject and Caverject Impulse, has periodically offered copay savings cards that reduce out-of-pocket costs for commercially insured patients. These programs typically cap patient copays at $30 to $50 per fill.

Key rules for manufacturer savings cards in Indiana: they apply only to patients with commercial insurance, not Medicaid, Medicare, or other government-funded plans. The savings card covers the gap between the patient's copay and a preset maximum (often $150 to $200 per fill). If the retail price exceeds the card's maximum benefit, the patient pays the difference. Cards are usually valid for 12 months and may limit the number of fills per year.

Generic alprostadil manufacturers may also offer patient assistance programs, though these are less standardized. The NeedyMeds database and RxAssist maintain updated directories of manufacturer assistance programs for alprostadil products.

For uninsured patients in Indiana, Pfizer's patient assistance program (Pfizer RxPathways) may provide Caverject at no cost to qualifying individuals whose household income falls below 400% of the federal poverty level. Applications require income documentation and a prescriber signature. Processing takes 4 to 6 weeks.

Telehealth Prescribing of Alprostadil in Indiana

Indiana permits telehealth prescribing of alprostadil. The state's telemedicine statute, IC 25-1-9.5, allows licensed physicians to prescribe medications via synchronous audio-video encounters, provided the physician is licensed in Indiana and establishes an appropriate provider-patient relationship.

Several telehealth platforms now prescribe alprostadil to Indiana residents after a video consultation and review of medical history. This process typically includes blood pressure screening, cardiovascular risk assessment, and documentation of PDE5 inhibitor trial or contraindication. The American Urological Association's 2018 ED guideline recommends that intracavernosal injection therapy include in-office dose titration and injection training. Some telehealth platforms coordinate this training through a local urology office or provide detailed video instruction, though in-person training remains the standard of care.

Telehealth consultations for alprostadil in Indiana range from $50 to $150 per visit. Some platforms bundle the consultation fee with compounded medication, creating a subscription model that covers both the prescriber visit and a 30-day supply of compounded trimix or alprostadil monotherapy. These bundled models often represent the lowest total monthly cost for Indiana patients paying out of pocket.

Comparing Alprostadil Formulations and Their Indiana Pricing

Three distinct alprostadil products are available in Indiana, each with different pricing and clinical profiles.

Caverject / Caverject Impulse (intracavernosal injection): The original FDA-approved injection. Caverject Impulse uses a pre-filled dual-chamber syringe that simplifies reconstitution. Indiana retail cash price for a 6-pack of Caverject Impulse 20 mcg averages $550 to $700. The Linet et al. trial established its efficacy at 87% of injections producing adequate erections at optimized dose in the clinic setting, with a 94% at-home success rate reported in follow-up data.

MUSE (intraurethral suppository): A 125 to 1 to 000 mcg alprostadil pellet inserted into the urethra via applicator. MUSE avoids needle injection but has lower efficacy. In the key MUSE trial (Padma-Nathan et al., NEJM 1997, N=1,511), 65.9% of MUSE-treated patients achieved erections sufficient for intercourse versus 18.6% with placebo. Indiana retail pricing for MUSE runs $400 to $700 per month depending on dose and quantity.

Compounded alprostadil / trimix (intracavernosal injection): Not FDA-approved as a finished product but widely used. Per-dose costs in Indiana: $5 to $15 from a licensed 503A pharmacy. Multi-dose vials require refrigeration and have a 30 to 90 day beyond-use date depending on the compounding pharmacy's stability data.

Reducing Your Out-of-Pocket Cost: A Step-by-Step Approach

Start by checking insurance formulary coverage. Call the number on your pharmacy benefit card and ask whether alprostadil (NDC for Caverject Impulse or MUSE) is covered, what tier it sits on, and whether prior authorization or step therapy applies.

If covered, ask your prescriber to submit prior authorization if required. Document any PDE5 inhibitor trials, contraindications (nitrate use, unstable cardiovascular disease), or prior adverse reactions. The AUA guideline supports second-line intracavernosal therapy after PDE5 inhibitor failure, which strengthens the prior authorization case.

If not covered or if copay is too high, request a manufacturer savings card from your prescriber's office or download one from the manufacturer's website. Apply the card at an Indiana retail pharmacy at fill time.

If uninsured or underinsured, ask your prescriber about compounded trimix from a licensed Indiana 503A pharmacy. This is the lowest-cost option for most patients. The prescriber writes a patient-specific prescription, and the compounding pharmacy dispenses the formulation directly or ships it with cold-pack packaging.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that for patients with ED refractory to testosterone replacement and PDE5 inhibitors, intracavernosal injection therapy is an appropriate next step, which may support insurance appeals when ED occurs in the context of documented hypogonadism.

Per-injection cost for compounded trimix at an Indiana 503A pharmacy averages $8 to $12 based on typical vial pricing and doses per vial, compared to $75 to $120 per injection for brand Caverject Impulse at retail cash price.